Discovery and Optimization of a Natural HIV-1 Entry Inhibitor Targeting the gp41 Fusion Peptide

A variety of molecules in human blood have been implicated in the inhibition of HIV-1. However, it remained elusive which circulating natural compounds are most effective in controlling viral replication in vivo. To identify natural HIV-1 inhibitors we screened a comprehensive peptide library generated from human hemofiltrate. The most potent fraction contained a 20-residue peptide, designated VIRUS-INHIBITORY PEPTIDE (VIRIP), corresponding to the C-proximal region of alpha1-antitrypsin, the most abundant circulating serine protease inhibitor. We found that VIRIP inhibits a wide variety of HIV-1 strains including those resistant to current antiretroviral drugs. Further analysis demonstrated that VIRIP blocks HIV-1 entry by interacting with the gp41 fusion peptide and showed that a few amino acid changes increase its antiretroviral potency by two orders of magnitude. Thus, as a highly specific natural inhibitor of the HIV-1 gp41 fusion peptide, VIRIP may lead to the development of another class of antiretroviral drugs.

[1]  J. Levy,et al.  CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. , 1986, Science.

[2]  P S Kim,et al.  Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[3]  R. Doms,et al.  HIV-1 coreceptors and their inhibitors. , 2006, Current topics in microbiology and immunology.

[4]  Shibo Jiang,et al.  Different from the HIV Fusion Inhibitor C34, the Anti-HIV Drug Fuzeon (T-20) Inhibits HIV-1 Entry by Targeting Multiple Sites in gp41 and gp120* , 2005, Journal of Biological Chemistry.

[5]  J. Levy.  The search for the CD8+ cell anti-HIV factor (CAF). , 2003, Trends in immunology.

[6]  A. Debnath,et al.  Peptide and non-peptide HIV fusion inhibitors. , 2002, Current pharmaceutical design.

[7]  L. Shapiro,et al.  Alpha‐1‐antitrypsin inhibits human immunodeficiency virus type 1 , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  A. Debnath,et al.  A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody. , 1999, Journal of virological methods.

[9]  G. Fields,et al.  Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. , 2009, International journal of peptide and protein research.

[10]  R. Crystal,et al.  Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms. , 1988, The American review of respiratory disease.

[11]  James K Stoller,et al.  α1-antitrypsin deficiency , 2005, The Lancet.

[12]  T. Merigan,et al.  Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. , 2004, The Journal of infectious diseases.

[13]  Michael S. Kay,et al.  Protein Design of an HIV-1 Entry Inhibitor , 2001, Science.

[14]  M. L. Penn,et al.  HIV-1 Vpr Enhances Viral Burden by Facilitating Infection of Tissue Macrophages but Not Nondividing CD4+ T Cells , 2001, The Journal of experimental medicine.

[15]  J. McArthur,et al.  Lentivirus Infection in the Brain Induces Matrix Metalloproteinase Expression: Role of Envelope Diversity , 2000, Journal of Virology.

[16]  E. Goetzl,et al.  Matrix metalloproteinases in immunity. , 1996, Journal of immunology.

[17]  H. Buc,et al.  HIV-1 reverse transcription. A termination step at the center of the genome. , 1994, Journal of molecular biology.

[18]  F. Kirchhoff,et al.  The most frequent naturally occurring length polymorphism in the HIV-1 LTR has little effect on proviral transcription and viral replication. , 2002, Virology.

[19]  Eric Hunter,et al.  Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry , 1998, Nature Medicine.

[20]  M. Raida,et al.  Systematic isolation of circulating human peptides: the concept of peptide trapping. , 1996, European journal of medical research.

[21]  P. Schulz-Knappe,et al.  Characterization of natural posttranslationally processed peptides from human blood: A new tool in the systematic investigation of native peptides , 1993 .

[22]  M. Schrader,et al.  Peptide bank generated by large-scale preparation of circulating human peptides. , 1997, Journal of chromatography. A.

[23]  R. Doms,et al.  Hemofiltrate CC Chemokine 1[9-74] Causes Effective Internalization of CCR5 and Is a Potent Inhibitor of R5-Tropic Human Immunodeficiency Virus Type 1 Strains in Primary T Cells and Macrophages , 2002, Antimicrobial Agents and Chemotherapy.

[24]  T. Matthews,et al.  Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides , 1998, Journal of Virology.

[25]  M. Stevenson.  HIV-1 pathogenesis , 2003, Nature Medicine.

[26]  Min Lu,et al.  A Conformation-Specific Monoclonal Antibody Reacting with Fusion-Active gp41 from the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein , 1998, Journal of Virology.

[27]  E. Veerman,et al.  A critical comparison of the hemolytic and fungicidal activities of cationic antimicrobial peptides , 1999, FEBS letters.

[28]  I. Kushner.  [35] The acute phase response: An overview , 1988 .

[29]  S. Weiss,et al.  Proteolytic inactivation of alpha-1-proteinase inhibitor by a neutrophil metalloproteinase. , 1988, The Journal of clinical investigation.

[30]  F. Kirchhoff,et al.  Natural Proteolytic Processing of Hemofiltrate Cc Chemokine 1 Generates a Potent Cc Chemokine Receptor (Ccr)1 and Ccr5 Agonist with Anti-HIV Properties , 2000, The Journal of experimental medicine.

[31]  I. Kushner,et al.  The acute phase response: an overview. , 1988, Methods in enzymology.

[32]  Shibo Jiang,et al.  Convenient cell fusion assay for rapid screening for HIV entry inhibitors , 2000, Photonics West - Biomedical Optics.

[33]  Peter C Gøtzsche,et al.  Alpha1-antitrypsin deficiency. , 2009, The New England journal of medicine.

[34]  W. Forssmann,et al.  Strategy for identifying circulating fragments of insulin-like growth factor binding proteins in a hemofiltrate peptide bank. , 1999, Journal of chromatography. A.

[35]  G. Salvesen,et al.  Human plasma proteinase inhibitors. , 1983, Annual review of biochemistry.

[36]  J. Sodroski,et al.  A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys , 1996, Journal of virology.

[37]  M. Greenberg,et al.  Resistance to enfuvirtide, the first HIV fusion inhibitor. , 2004, The Journal of antimicrobial chemotherapy.

[38]  J. Takehisa,et al.  Analysis of a primary isolate-like virus from simian and human immunodeficiency virus-infected macaque having broad neutralizing activity. , 2002, AIDS research and human retroviruses.

[39]  A. Waring,et al.  The amino-terminal peptide of HIV-1 glycoprotein 41 lyses human erythrocytes and CD4+ lymphocytes. , 1992, Biochimica et biophysica acta.

[40]  Douglas S Kwon,et al.  DC-SIGN, a Dendritic Cell–Specific HIV-1-Binding Protein that Enhances trans-Infection of T Cells , 2000, Cell.

[41]  B. Schmidt,et al.  Phenotypic HIV-1 Resistance Correlates with Treatment Outcome of Nelfinavir Salvage Therapy , 1999, Antiviral therapy.

[42]  S. A. Gallo,et al.  θ-Defensins Prevent HIV-1 Env-mediated Fusion by Binding gp41 and Blocking 6-Helix Bundle Formation* , 2006, Journal of Biological Chemistry.

[43]  L. Thomas,et al.  Inhibition of HIV-1 gp160-dependent membrane fusion by a furin-directed alpha 1-antitrypsin variant. , 1993, The Journal of biological chemistry.

[44]  Stephen C. Blacklow,et al.  A trimeric structural domain of the HIV-1 transmembrane glycoprotein , 1995, Nature Structural Biology.

[45]  John P. Moore,et al.  New targets for inhibitors of HIV-1 replication , 2000, Nature Reviews Molecular Cell Biology.

[46]  A. Waring,et al.  Membrane-perturbing domains of HIV type 1 glycoprotein 41. , 2001, AIDS research and human retroviruses.

[47]  M. Zenke,et al.  Infection of mature dendritic cells with herpes simplex virus type 1 dramatically reduces lymphoid chemokine-mediated migration. , 2005, The Journal of general virology.

[48]  H. Klenk,et al.  Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gpl60 , 1992, Nature.

[49]  B. Clotet,et al.  HIV-1 resistance to the gp41-dependent fusion inhibitor C-34. , 2003, Antiviral research.